文献速递肝病消化道出血

静脉羧基麦芽糖铁与口服铁剂治疗肝硬化食管胃静脉曲张出血后缺铁性贫血的随机对照试验

Randomized Controlled Trial of Intravenous Ferric Carboxymaltose vs Oral Iron to Treat Iron Deficiency Anemia After Variceal Bleed in Patients With Cirrhosis.
PubMed 文献 · Am J Gastroenterol · 2024-03-22

这项开放标签、单中心随机对照试验比较静脉羧基麦芽糖铁与口服铁剂治疗肝硬化静脉曲张出血后缺铁性贫血的疗效与安全性。静脉组3个月血红蛋白中位增幅3.65 g/dL,高于口服组的1.10 g/dL(P<0.001),铁储备正常化率84.6% vs 21%(P<0.001),贫血改善率50% vs 21.9%(P<0.009)。静脉组43%出现一过性轻/中度低磷血症,肝脏相关不良事件两组相当。

要点

  • 静脉羧基麦芽糖铁3个月血红蛋白中位增幅3.65 g/dL,口服铁剂为1.10 g/dL(P<0.001)。
  • 静脉组铁储备正常化84.6%、贫血改善50%,均高于口服组的21%和21.9%。
  • 静脉组43%发生一过性轻/中度低磷血症,肝脏相关不良事件两组相当。

核心结论

  • 静脉补铁治疗肝硬化患者静脉曲张出血后缺铁性贫血有效且安全。

研究设计与样本

  • 开放标签、单中心随机对照试验,纳入静脉曲张出血后血红蛋白<10 g/dL且铁蛋白<100 ng/mL的肝硬化患者。
  • 静脉羧基麦芽糖铁组48例,给予1,500-2,000 mg分2次给药;口服羰基铁组44例,给予元素铁100 mg/天,疗程3个月。
  • 主要结局为3个月时血红蛋白变化,次要结局包括贫血改善、铁储备正常化、肝脏相关不良事件、药物不良反应及生活质量变化。

主要发现

  • 3个月血红蛋白中位增幅静脉组3.65 g/dL(IQR 2.55-5.25)vs 口服组1.10 g/dL(IQR 0.05-2.90)(P<0.001)。
  • 铁储备正常化率静脉组84.6% vs 口服组21%(P<0.001)。
  • 贫血改善率静脉组50% vs 口服组21.9%(P<0.009)。
  • 静脉组CLDQOL所有领域均显示显著改善,肝脏相关不良事件两组相当。
  • 静脉羧基麦芽糖铁组43%出现一过性轻/中度低磷血症。

临床怎么用

  • 原文结论认为静脉补铁是肝硬化患者静脉曲张出血后缺铁性贫血的有效且安全治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Limited evidence exists on the optimal strategy to correct iron deficiency anemia after variceal bleeding (VB) in cirrhosis. This trial compared the efficacy and safety of intravenous ferric carboxymaltose (IV-FCM) with those of oral iron therapy in this cohort. METHODS: In this open-label, single-center, randomized controlled trial, eligible patients with hemoglobin <10 g/dL and iron deficiency (ferritin <100 ng/mL) after VB received either IV-FCM (1,500-2,000 mg) divided into 2 doses (n = 48) or oral carbonyl iron (100 mg elemental iron/day) (n = 44) for 3 months. The primary outcome was change in hemoglobin at 3 months. Secondary outcomes included improvement in anemia (last hemoglobin >12 g/dL), normalization of iron stores (ferritin >100 ng/mL), liver-related adverse events, adverse drug reactions, and changes in quality of life (CLDQOL questionnaire). RESULTS: Baseline characteristics, including median Child-Turcotte-Pugh score 7 (interquartile range [IQR] 6-9), Model for End-Stage Liver Disease score 12 (IQR 10-17), blood hemoglobin (8.25 ± 1.06 g/dL), and ferritin (30.00 ng/mL [15.00-66.50]), were comparable in both arms. The median increase in hemoglobin at 3 months in the IV and oral arms was 3.65 g/dL (IQR 2.55-5.25) and 1.10 g/dL (IQR 0.05-2.90 g/dL) ( P < 0.001), respectively. Iron stores normalized in 84.6% and 21% of the IV and oral arms, respectively ( P < 0.001). Anemia improved in 50% and 21.9% in the IV and oral arms, respectively ( P < 0.009). Patients in the IV arm showed a significant improvement in all domains of CLDQOL. Liver-related adverse events were comparable in both arms. Transient mild/moderate hypophosphatemia developed in 43% of patients receiving IV-FCM. DISCUSSION: Intravenous iron replacement is efficacious and safe to treat iron deficiency anemia after VB in patients with cirrhosis.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Tabish M, Agarwal S, Gopi S, et al. Randomized Controlled Trial of Intravenous Ferric Carboxymaltose vs Oral Iron to Treat Iron Deficiency Anemia After Variceal Bleed in Patients With Cirrhosis. Am J Gastroenterol. 2024. PMID: 38517084. doi:10.14309/ajg.0000000000002775

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。